RGLS

Regulus Therapeutics Inc. Common Stock NASDAQ Global Market
$1.03
Open: $0.965 High: $1.04 Low: $0.952 Close: $1.02
Range: 2021-06-23 - 2021-06-24
Volume: 7,226,640
Market: Open
Powered by Finage Stock APIDelayed data
RGLS
Regulus Therapeutics Inc. Common Stock 10614 Science Center Drive San Diego CA, 92121 http://www.regulusrx.com
Regulus Therapeutics Inc is a biotechnology company that focuses on the development of microRNA therapies. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome.
  • CEO: Joseph P. Hagan
  • Employees: 60
  • Sector: Healthcare
  • Industry: Biotechnology
RGLS News
Latest news about the RGLS
  • Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it will present new preclinical data and additional clinical data from the first cohort of patients in the Company's Phase 1b clinical trial of RGLS4326 for the treatment of ADPKD at the PKD Connect Conference 2021, being held virtually Friday, June 25.

    View More →
  • Do Options Traders Know Something About Regulus Therapeutics (RGLS) Stock We Don't?

    Investors need to pay close attention to Regulus Therapeutics (RGLS) stock based on the movements in the options market lately.

    View More →
  • Regulus's Polycystic Kidney Disease Candidate Shows Benefit At Interim Analysis

    Regulus Therapeutics Inc (NASDAQ: RGLS) has announced an incremental update from the first cohort of patients from its ongoing Phase 1b trial evaluating RGLS4326 in Autosomal Dominant Polycystic Kidney Disease (ADPKD). ADPKD is a genetic disorder characterized by the growth of numerous cysts in the kidneys. In the first cohort, nine patients were enrolled and received 1 mg/kg of RGLS4326 subcutaneously every other week for four doses. The mean increase in polycystins 1 and 2 (lower protein levels associated with ADPKD) at the end of the study compared to baseline levels for all nine patients in the first cohort was 58% (p=.0004) 38%, respectively. As disclosed earlier, treatment with RGLS4326 was generally well-tolerated with no serious adverse events reported. All reported adverse events were mild and generally transient. These data will be presented at the Oppenheimer Rare & Orphan Disease Summit today. Additional data from this first cohort will be presented at PKD Connect in June 2021, and an abstract will be submitted to the American Society of Nephrology annual meeting in November. Data from the second cohort is expected in the third quarter. Price Action: RGLS shares are down 3.1% at $0.92 on the last check Friday. See more from BenzingaClick here for options trades from BenzingaVBI Vaccines Secures M In Second Tranche of Debt Financing With K2 HealthVenturesAnnovis Bio's Stock Trading Higher As Alzheimer's/Parkinson's Candidate Shows Cognitive Improvement© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced an incremental update from the first cohort of patients with ADPKD in its ongoing Phase 1b clinical trial of RGLS4326. The study is evaluating the safety, pharmacokinetics, and effects on pharmacodynamic biomarkers of multiple doses of RGLS4326 in patients with ADPKD.

    View More →
  • Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 11:35 A.M. ET.

    View More →
  • Regulus (RGLS) Reports Q1 Loss, Misses Revenue Estimates

    Regulus (RGLS) delivered earnings and revenue surprises of 11.11% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    View More →
  • Regulus Therapeutics Reports First Quarter 2021 Financial Results and Recent Updates

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update.

    View More →
  • Regulus Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Regulus Therapeutics, Inc. (NASDAQ:RGLS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 5:00 PM Eastern Time.

    View More →
  • Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    View More →
  • Regulus Therapeutics' RGLS4326 Reports Mixed Bag On Polycystic Kidney Disease-Associated Biomarker Study

    Regulus Therapeutics Inc (NASDAQ: RGLS) has announced top-line results from the first cohort of patients (n=9) with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in its ongoing Phase 1b trial of RGLS4326. The study evaluates the safety, pharmacokinetics, and effects on pharmacodynamic biomarkers of multiple doses of RGLS4326. RGLS4326 was well tolerated by all nine patients, with no serious adverse events reported. All reported adverse events were mild and generally transient in nature. A statistically significant increase in the PC1 biomarker was observed in the first cohort of this study. The mean increase at Day 71 (n=8) compared to baseline was greater than 50%, and all patients had a double-digit rise in Polycystin 1 (PC1) levels with an overall trend showing increasing levels of both PC1 and Polycystin 2 (PC2) over time. Mean PC2 levels increased compared to baseline levels (more than 20%). However, the results did not reach statistical significance. Regulus believes these initial data demonstrate that RGLS4326 engages the target miR-17 leading to de-repression of the PKD1 and PKD2 genes and the resultant increases in measured Polycystin levels. Another notable improvement was observed in neutrophil gelatinase-associated lipocalin (NGAL) levels for one patient in the first cohort. As anticipated, NGAL levels for nearly all patients in this study were within the normal range. However, one patient had approximately twice the normal range at baseline, and that individual saw NGAL levels drop to within the normal range by the end of the study. Data from this first cohort is planned to be submitted for presentation at Kidney Week, the American Society of Nephrology annual meeting held in November 2021. Regulus will host a conference call and webcast at 8:30 a.m. Eastern Time today. Price Action: RGLS shares are down 2.88% at $1.35 in the premarket on the last check Monday. See more from BenzingaClick here for options trades from BenzingaAmicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe DiseaseOcugen Shares Gain After Its Partner's COVID-19 Vaccine Shows Effectiveness Against Multiple Variants© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced top-line results from the first cohort of patients with ADPKD in its ongoing Phase 1b clinical trial of RGLS4326. The study is evaluating the safety, pharmacokinetics, and effects on pharmacodynamic biomarkers of multiple doses of RGLS4326 in patients with ADPKD.

    View More →
  • Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it completed dosing in the first cohort of nine patients with ADPKD in its Phase 1b clinical trial of RGLS4326. The study is evaluating the safety, pharmacokinetics, and biomarkers (polycystin 1 (PC1) and polycystin 2 (PC2)) of multiple doses of RGLS4326 in patients with ADPKD.

    View More →
  • Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the 20th Annual Needham Healtchare Conference on Thursday, April 15th at 1:30 P.M. ET.

    View More →
  • Investors Who Bought Regulus Therapeutics (NASDAQ:RGLS) Shares A Year Ago Are Now Up 101%

    Regulus Therapeutics Inc. ( NASDAQ:RGLS ) shareholders have seen the share price descend 10% over the month. But that...

    View More →
  • Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.

    View More →
  • Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually on March 9-10, 2021.

    View More →
  • Will Regulus (RGLS) Report Negative Q4 Earnings? What You Should Know

    Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    View More →
  • Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment of the first cohort of patients into its Phase 1b clinical study of RGLS4326. The Phase 1b is an adaptive design, open-label, multiple dose study in up to three cohorts of patients with ADPKD. The study is designed to evaluate the safety, pharmacokinetics, and changes in levels of polycystin 1 (PC1) and polycystin 2 (PC2) in patients with ADPKD administered RGLS4326 every other week for a total of four doses. The dose level for the first cohort is 1mg/kg of RGLS4326 and the dose level for the second cohort is 0.3mg/kg. The third and final cohort will be dosed at a level to be determined based on the results of the first two cohorts. Concurrent with completion of enrollment in the first cohort and based on the review of the available interim safety data, the first patient of the second cohort has received the first dose of RGLS4326.

    View More →
  • Regulus Announces Addition to Board of Directors

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Alice S. Huang, Ph.D. has been appointed to the Company's board of directors. Concurrently with her appointment to the Board, Dr. Huang was appointed to serve on the Compensation Committee.

    View More →
  • Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

    Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the H.C. Wainwright Virtual BioConnect Conference being held from January 11-14, 2021.

    View More →